Gonorrhea drug zoliflodacin put to the test: will it harm male fertility?
NCT ID NCT07640477
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will give 200 healthy men a single dose of either zoliflodacin or a placebo to see if the drug affects sperm count, movement, shape, or hormone levels. Participants provide semen and blood samples before and 13 weeks after dosing. If a significant drop in sperm concentration is seen, they will be followed for another 13 weeks to check if the effect reverses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zoliflodacin
- What this could lead to
- If this trial shows no harm to testicular function, it would support zoliflodacin as a safe treatment option for gonorrhea without affecting male fertility.
- What could go wrong
- This is a safety study in healthy volunteers, not a treatment trial. It only looks at short-term effects after one dose, so long-term risks remain unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TESTICULAR ABNOMINALIES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Parexel EPCU
Berlin, Germany
-
Parexel EPCU
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.